Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2004 September;29(3) > Minerva Endocrinologica 2004 September;29(3):89-112

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  THE HEART AND ENDOCRINOLOGY


Minerva Endocrinologica 2004 September;29(3):89-112

language: English

Slaying the metabolic syndrome.Are we battling the Hydra or the Chimera?

Dunbar R. L., Rader D. J.


PDF  


Metabolic syndrome is the latest moniker for an alliance of pathologic conditions that conspire to amplify the risk of atherosclerosis or type 2 diabetes. Several recent advances in the understanding of this condition have led to its widespread adoption in clinical practice, prompted by influential practice guidelines. In particular, guidelines relating to the management of hyperlipidemia and hypertension afford a prominent role for metabolic syndrome, as a risk factor and a target of therapy. In many ways, the scientific evidence base has not kept pace with the demand for treatment options, rendering therapy nebulous. Most prominently, we do not know whether to adopt a strategy based on a multi-pronged attack, or whether to concentrate our greatest efforts on attacking a critical weakness. We review the limited data available regarding metabolic syndrome, with a focus on expert opinion gleaned from clinical guidelines, and offer advice to the clinician from our own experience with this population.

top of page

Publication History

Cite this article as

Corresponding author e-mail